

The regulation of non-invasive medical devices in Australia: a case study of breast cancer imaging devices marketed direct-to-consumer

Thomas Vreugdenburg

BHealthSciences(Hons)

A thesis submitted in fulfilment of the requirements for
the degree of Doctor of Philosophy

August 2014

Discipline of Public Health

School of Population Health

Faculty of Health Sciences

The University of Adelaide

Table of contents

Thesis summary	V
Declaration	VII
Conference presentations resulting from this thesis	VIII
Peer-reviewed journal articles resulting from this thesis	IX
Acknowledgements	X
List of tables	XI
List of figures	XII
List of terms	XIII
Chapter 1 - Introduction and literature review	1
1.1 Introduction.....	2
1.2 Health services research and the regulation of medical devices	2
1.2.1 Pathway to market: pre-market conformity assessment of medical devices in Australia	5
1.2.2 Risk management approach to medical device regulation	7
1.3 Medical devices advertised directly towards consumers	12
1.3.1 Regulating dtca of medical devices in Australia.....	12
1.4 Challenges to the effective regulation of devices and their advertising material	13
1.4.1 Debate around the benefit of dtca	14
1.5 Case study: emerging breast cancer imaging devices	17
1.5.1 Clinical relevance and burden of disease in Australia	17
1.5.2 Australia’s national breast cancer screening program	19
1.6 Emerging breast imaging devices	22
1.6.1 Digital infrared thermal imaging (DITI)	22
1.6.2 Electrical impedance scanning (EIS)	23
1.6.3 Electronic palpation imaging (EPI).....	25
1.6.4 The evidence base for DITI, EIS and EPI	26
1.7 Gaps in evidence base and research justification	27
1.8 Research aims and questions.....	28
1.9 Thesis outline	29

Chapter 2 - Policy issues surrounding DtCA of breast imaging devices in Australia ...	31
2.1 Preface to Chapter 2.....	32
2.2 Statement of authorship.....	33
2.3 Abstract	34
2.4 Introduction.....	34
2.5 Importance of breast cancer screening and diagnostic devices	35
2.6 Pre-market regulation of medical devices in Australia	37
2.7 Post-market regulation of dtca in Australia.....	39
2.8 Conclusion and implications.....	41
Chapter 3 - Evaluating the evidence base: a systematic review of emerging breast imaging devices	43
3.1 Preface to Chapter 3.....	44
3.2 Statement of authorship.....	45
3.3 Abstract	46
3.4 Introduction.....	47
3.5 Methods.....	48
3.5.1 Search strategy	48
3.5.2 Study selection	48
3.5.3 Data extraction and quality appraisal.....	48
3.5.4 Data synthesis.....	49
3.6 Results	50
3.6.1 Literature search results	50
3.6.2 Risk of bias within studies.....	51
3.6.3 Publication bias	52
3.6.4 Investigation of heterogeneity.....	52
3.6.5 Synthesis of results	57
3.7 Discussion	59
3.8 Conclusions	61
3.8.1 Acknowledgements	62
Chapter 4 - Content analysis of online DtCA of emerging breast imaging devices.....	63
4.1 Preface to Chapter 4.....	64
4.2 Statement of authorship.....	65

4.3	Abstract	67
4.4	Introduction.....	68
4.5	Methods.....	69
4.5.1	Search strategy	69
4.5.2	Codebook development	69
4.5.3	Coder training.....	69
4.5.4	Data analysis.....	70
4.6	Results	70
4.6.1	Device performance	71
4.6.2	Application of device	71
4.6.3	Device safety.....	72
4.6.4	Target population	73
4.6.5	Comparison with conventional breast imaging technology.....	73
4.6.6	Change over time.....	74
4.7	Discussion	75
4.7.1	Acknowledgements	77
4.7.2	Competing interests	77
Chapter 5 - Exploring options to reform the regulation of medical devices and medical device advertising		79
5.1	Introduction.....	80
5.1.1	The TGA reform process	81
5.1.2	Research aims and objectives.....	83
5.2	Methods.....	85
5.2.1	Design.....	85
5.2.2	Stakeholder selection and recruitment.....	85
5.2.3	Interview schedule.....	86
5.2.4	Data analysis.....	87
5.2.5	Ethical requirements.....	87
5.3	Results	88
5.3.1	Stakeholder demographics.....	88
5.3.2	Section 1: The TGA's proposals to reform the pre-market assessment of medical devices.....	89

5.3.3	Section 2: The TGA's options to reform the advertising arrangements for medical devices in Australia	96
5.3.4	Section 3: Recommended criteria for the pre-market assessment of medical devices, and medical device advertising	100
5.4	Discussion	105
5.4.1	Limitations	107
5.4.2	Conclusions and policy considerations	108
Chapter 6	- Discussion and conclusions	109
6.1	Introduction	110
6.2	Key findings and implications	110
6.2.1	What is the available evidence of safety, effectiveness and diagnostic accuracy of digital infrared thermal imaging (DITI), electrical impedance scanning (EIS) and electronic palpation imaging (EPI) for breast cancer screening and diagnosis?	110
6.2.2	What is the nature and frequency of advertising claims made on Australian websites for DITI, EIS and EPI? To what extent are claims made on websites for these devices supported by evidence?	112
6.2.3	What are the strengths and weaknesses of the TGA's proposed reforms to the pre-market assessment of medical devices and their advertising material in Australia? Which characteristics of medical devices and their advertising should be assessed by an independent regulator?	114
6.3	Thesis limitations and recommendations for future research	116
6.4	Conclusion	118
Appendix A	- Peer reviewed publications arising from this thesis	119
Appendix B	- Supplementary material for the systematic review publication	123
Appendix C	- Supplementary material for the content analysis	133
Appendix D	- Supplementary material for the stakeholder engagement	139
Appendix E	- TGA submission: premarket assessment of devices	153
Appendix F	- TGA submission: regulation of therapeutic goods advertising	167
Reference list	181

Thesis summary

Background

The premarket assessment of medical devices by an independent regulator is necessary to ensure that devices are safe and effective before they are made available to consumers in Australia. This responsibility is further necessitated by the practice of direct-to-consumer advertising (DtCA), whereby devices can be promoted to, and accessed by consumers without the involvement of a registered healthcare practitioner. An increase in the number of complaints against medical device advertising in Australia has raised questions around the effectiveness of the current regulations at ensuring that devices and their advertising material are adequately supported by evidence.

Aims

The aim of this thesis is to explore the relationship between scientific evidence and DtCA in the policy context of medical device regulation in Australia. This aim is investigated using a case study of three emerging breast cancer imaging devices: digital infrared thermal imaging (DITI), electronic impedance scanning (EIS) and electronic palpation imaging (EPI). In this thesis, the evidence supporting the safety and effectiveness of these devices is evaluated, the nature and frequency of claims presented in online advertisements for these devices are assessed and compared against the available evidence, and stakeholders are engaged in a discussion around options to reform the regulation of medical devices and medical device advertising.

Methods

A mixed methods approach was undertaken, involving three interrelated studies. The first study presents a systematic review of the available evidence for the safety and effectiveness of DITI, EIS and EPI. Following the systematic review, a quantitative content analysis was used to investigate the evidentiary basis of advertising claims made on websites that promote DITI, EIS and EPI in Australia. Finally, the results of the first two studies were used to inform stakeholder engagement around options to reform the regulation of medical devices and medical device advertising. Thematic analysis was used to synthesise stakeholder preferences in relation to a series of reform options proposed by Australia's principal therapeutic goods regulator, the Therapeutic Goods Administration (TGA).

Results

Study 1

As no direct effectiveness data were identified, the surrogate outcome measure of diagnostic accuracy became the primary focus of the systematic review. Significant heterogeneity was present among all three device classes, limiting the potential for meta-analyses. There was insufficient evidence to support the use of DITI, EIS or EPI for breast cancer screening, and the reported estimates of the sensitivity and specificity in symptomatic populations varied greatly for DITI (Sens 0.25-0.97, Spec 0.12-0.85) and EIS (Sens 0.26-0.98, Spec 0.08-0.81), while only two poor quality studies were identified for EPI.

Study 2

Thirty-nine Australian websites promoting DITI, EIS or EPI were identified. Despite a lack of primary evidence identified in the prior systematic review, the devices were advertised for diagnosis (n = 22 websites), screening (n = 20), prevention (n = 13) and risk factor identification for breast cancer (n = 13). Similarly, advertising claims of diagnostic accuracy (Sens 0.78-0.99, Spec 0.44-0.91) did not reflect the evidence base. Direct comparisons with conventional imaging were highly prominent (n = 31), and one third of websites explicitly promoted their device as a suitable alternative to conventional imaging (n = 12).

Study 3

Sixteen stakeholders representing breast cancer research, patient advocacy and screening provided input into reforms to premarket medical device regulation and advertising proposed by the TGA. Participants highlighted important benefits and limitations of the proposed options. Differences between the TGA's options for reform and stakeholder views indicated a need to update the current model for regulation that allows consumer choice and supports innovation, but within a more tightly regulated, safety-oriented framework.

Conclusion

Online advertising claims made for DITI, EIS and EPI extend the indications and efficacy of these devices beyond the available research evidence. This disconnect suggests the regulatory framework tasked with ensuring the safety and efficacy of these devices and their promotion is in need of reform. Extending the current regulations for advertising pre-approval to include medical devices, assessing diagnostic imaging devices for efficacy prior to market, and monitoring the use of a device in practice compared to its approved use on the Australian Register of Therapeutic Goods (ARTG) will help close the gap between DtCA and the evidence for emerging breast imaging devices.

Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Signed:

Date:

Conference presentations resulting from this thesis

1. **Vreugdenburg TD**, Willis C, Mundy L, Hiller JE. Direct-to-consumer breast cancer imaging devices: A systematic review of their effectiveness in diagnostic and screening settings. [Oral] 29th Annual Meeting, The International Society for Quality in Health Care. Geneva, Switzerland, October 21-24, 2012.
2. **Vreugdenburg TD**, Laurence CO, Willis CD, Mundy L, Hiller JE. Content analysis of advertisements for emerging breast cancer imaging devices. [Poster] Faculty of Health Sciences Postgraduate Research Conference. Adelaide, Australia, August 31, 2012.
3. **Vreugdenburg TD**, Willis CD, Mundy L, Hiller JE. Direct-to-consumer breast cancer imaging devices: A systematic review of their diagnostic and screening effectiveness. [Oral] 9th Annual Meeting, Health Technology Assessment International (HTAi). Bilbao, Spain, June 25-27, 2012.
4. **Vreugdenburg TD**, Willis CD, Mundy L, Hiller JE. A systematic review of thermography, electrical impedance, and elasticity imaging for breast cancer screening and diagnosis. [Poster] BreastScreen Australia Conference, Melbourne, Australia, October 28-30, 2011.
5. **Vreugdenburg TD**, Willis CD, Mundy L, Hiller JE. Emerging breast cancer imaging devices: a systematic review of their diagnostic and screening effectiveness. [Poster] 7th Health Services and Policy Research Conference. Adelaide, Australia, December 5-7, 2011.

Peer-reviewed journal articles

resulting from this thesis

1. **Vreugdenburg TD**, Laurence CO, Willis CD, Mundy L, Hiller JE. Content analysis of online direct-to-consumer advertising for emerging breast cancer imaging devices. *The Medical Journal of Australia*, 2014: 201(1); 289-294.
2. **Vreugdenburg TD**, Willis CD, Mundy L, Hiller JE. A systematic review of elastography, electrical impedance scanning, and digital infrared thermography for breast cancer screening and diagnosis. *Breast Cancer Research and Treatment*, 2013: 137(3); 665-676.
3. **Vreugdenburg TD**, Willis CD, Mundy L, Hiller JE. 2013. Pre-market approval and post-market direct-to-consumer advertising of medical devices in Australia: a case study of breast cancer screening and diagnostic devices. *Internal Medicine Journal*, 2013: 43(1); 53-58.

Acknowledgements

A number of people helped guide me through this PhD candidature, offering motivation, guidance, support, and time. To these people I am sincerely grateful, and would like to offer thanks.

First and foremost, my supervisors: Janet Hiller, for generously offering her time, intellect and genuine passion for public health, proving in the process that there are in fact more than 24 hours in a day. Cameron Willis, for providing a truly endless source of motivation and support, and offering guidance and input into every aspect of my role of as a PhD candidate. Caroline Laurence, who joined the panel partway through my candidature, and lent her level-headed pragmatism to anchor the content analysis and stakeholder engagement studies. Linda Mundy, for contributing her vast knowledge of systematic review methodology, and for playing the role of informal editor with so much enthusiasm that I still have nightmares about incorrectly using the letter 'z'.

Tracy Merlin, Jacqueline Street, Liz Buckley, Dagmara Riitano, David Johnson, Danika Hall, Shona Crabb, and Tom Sullivan, for assisting on various projects presented in this thesis, with only free beer, lunch or reciprocity as an incentive.

Adam Elshaug, for providing valuable input into the direction of this thesis during the early stages of conception.

I highly recommend that every commencing PhD candidate find a resident philosopher, like Drew Carter, to bounce ideas off and help guide them through inevitable crises.

Alun Cameron and Wendy Babidge from ASERNIP-s, for understanding the pressures associated with completing a PhD thesis, and for allowing me to work at a reduced capacity while finishing the write up.

My fellow inmates: Tori, Phi, David, Vicki, Icha, Kerri, and Andrew, for helping discuss and empathise with the big and small issues of life as a postgraduate student.

My friends and family, who remained genuinely interested in my thesis topic at every barbeque over the course of my candidature.

And my loving partner, Sharon, who survived 18 months at long-distance, and an equal amount of time dealing with the phrase "not-this-weekend-I'm-still-working-on-my-thesis".

List of tables

Table 1.1	NHMRC hierarchy of evidence according to research question	4
Table 1.2	Examples of medical devices under different risk categories	7
Table 1.3	Australian conformity assessment requirements for different classes of medical devices, adapted from the Australian regulatory guidelines for medical devices ...	9
Table 3.1	Characteristics of studies included in the systematic review	53
Table 4.1	Reliability score for each main code category	70
Table 4.2	Advertising content on direct-to-consumer websites for breast cancer imaging devices, by code category and device classification	71
Table 4.3	Examples of advertising claims and supporting evidence reported on direct-to-consumer websites for breast cancer imaging devices	74
Table 5.1	Participant demographics	88
Table 5.2	Stakeholder perspectives on the proposals for reform to the pre-market assessment of medical devices	89
Table 5.3	stakeholder perspectives on options to reform advertising regulations for medical devices	96
Table 5.4	Illustrative quotes demonstrating themes identified from participants regarding the pre-market approval of devices.....	101
Table 5.5	Illustrative quotes of themes identified from participants views regarding the assessment of advertising material for medical devices.....	103
eTable 1	Systematic review search strategy.....	124
eTable 2	Inclusion and exclusion criteria based on pico criteria.....	124
eTable 3	NHMRC hierarchy of evidence according to research question	125
eTable 4	Diagnostic accuracy results of included studies	126
eTable 5	Investigation of heterogeneity in subgroup likelihood ratios	129
eTable 6	Explanation of the QUADAS quality appraisal tool, as adapted for the systematic review	130

List of figures

Figure 1.1	Algorithm to determine the risk classification of an active medical device.....	8
Figure 1.2	Pathway of supply for medical devices in Australia.....	10
Figure 1.3	Technology adoption curve with possible patterns of diffusion	11
Figure 1.4	Age standardised incidence of breast cancer by age at diagnosis, females, 1982-2009.....	18
Figure 1.5	Clinical pathway for screening and diagnosis of breast cancer in Australia	20
Figure 1.6	Examples of thermography imaging results	23
Figure 1.7	Examples of electrical impedance imaging results.....	24
Figure 1.8	Examples of elastography imaging results	25
Figure 3.1	PRISMA flow diagram of study inclusion	50
Figure 3.2	Forest plot of estimated sensitivity and specificity reported in ultrasound elastography studies that employed the elasticity score method.....	57
Figure 3.3	Forest plot of estimated sensitivity and specificity reported in digital infrared thermal imaging studies, all methods.....	58
Figure 3.4	Forest plot of estimated sensitivity and specificity reported in electrical impedance scanning studies that employed the 5 point “level of suspicion” method.....	58
Figure 3.5	Forest plot of estimated sensitivity and specificity reported in electrical impedance scanning	58
Figure 5.1	Approximate timeline of the major reviews contributing to the TGA’s blueprint for reform package	81
eFigure 1	Percentage of all studies fulfilling individual QUADAS criteria	131
eFigure 2	Individual study estimates of sensitivity and specificity for use using artificial neural networks.....	131
eFigure 3	Individual study estimates of sensitivity and specificity for use using length ratio	131
eFigure 4	Individual study estimates of sensitivity and specificity for use using strain ratio.	132

List of terms

ACCC	Australian Competition and Consumer Commission
AIMD	Active Implantable Medical Device
ARTG	Australian Register of Therapeutic Goods
ASMI	Australian Self Medication Industry
ANZHSN	Australia and New Zealand Horizon Scanning Network
AusPAR	Australian Public Assessment Report
CAM	Complementary and Alternative Medicine
CBE	Clinical Breast Examination
CHC	Complementary Healthcare Council of Australia
CINAHL	Cumulative Index to Nursing and Allied Health Literature
CRD	Centre for Reviews and Dissemination
CRP	Complaints Resolution Panel
Cth	Commonwealth
DALY	Disability Adjusted Life Year
DITI	Digital Infrared Thermal Imaging
DM	Digital Mammography
DtCA	Direct-to-Consumer Advertising
EBM	Evidence Based Medicine
EIS	Electrical Impedance Scanning
EPI	Electronic Palpation Imaging
FDA	Food and Drug Administration
GHTF	Global Harmonization Task Force
GMDN	Global Medical Device Nomenclature
HTA	Health Technology Assessment
LOS	Level of Suspicion
MRI	Magnetic Resonance Imaging

NHMRC	National Health and Medical Research Council
OTC	Over-The-Counter
PRL	Proportional Reduction in Loss
QD	Qualitative Description
QUADAS	Quality Assessment of Diagnostic Accuracy Studies
TGA	Therapeutic Goods Administration
US	Ultrasound
USA	United States of America
USE	Ultrasound Elastography
YLD	Years Lost to Disability
YLL	Years of Lost Life